drug
as of 2026-07-01AQW051
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Novartis Pharmaceuticals
2 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
2
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
NCT01730768Phase 2Completed
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
NCT00825539Phase 1, Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication